Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1522)	3/7/2000 9:20:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

(trying to be Nigel)...... Tuesday March 7, 5:50 pm Eastern Time Company Press Release SOURCE: Corixa Corporation Corixa Files Registration Statement for Follow-On Public Offering Of 2,250,000 Shares of Common Stock SEATTLE, March 7 /PRNewswire/ -- Corixa Corporation (Nasdaq: CRXA - news) today announced it has filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed follow-on public offering of 2,250,000 shares of Common Stock. Corixa is a biotechnology company focused on understanding and directing the immune system to treat and prevent autoimmune diseases, cancer and infectious diseases. Of the 2,250,000 shares of Common Stock proposed to be offered, 2,000,000 are being offered by the Company and 250,000 are being offered by a selling stockholder of the Company. The shares will be offered by an underwriting group led by Warburg Dillon Read LLC, Lehman Brothers Inc., Prudential Vector Healthcare, a unit of Prudential Securities, and Pacific Growth Equities, Inc. (snip)